12月1日 07:00 GMT
澳门在线赌城娱乐 has agreed to sell the rights to 可定 (rosuvastatin) and associated medicines in over 30 countries in Europe, 除了英国和西班牙, to Grünenthal GmbH (Grünenthal). 可定 is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia.
路德浮标, Executive Vice President, 澳门第一赌城在线娱乐 Business Unit, said: “This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing new, innovative treatments to patients. Grünenthal previously acquired the rights to several established 澳门在线赌城娱乐 medicines and is well placed to ensure continued access to 可定 for patients across Europe.”
澳门在线赌城娱乐 will continue to manufacture and supply 可定 to Grünenthal during a transition period. 澳门在线赌城娱乐 will also continue selling the medicine in other countries, including those in North America, 在日本, China and other emerging markets.
Financial considerations
The divestment is anticipated to close in the first quarter of 2021, subject to customary closing conditions and regulatory clearances, upon which Grünenthal will make an upfront, non-contingent payment to 澳门在线赌城娱乐 of $320m and may also make future milestone payments of up to $30m. Income arising from the upfront and future payments will be reported in 澳门在线赌城娱乐’s financial statements within Other Operating Income & 费用. The divestment will not impact the Company’s financial guidance for 2020.
Pursuant to London Stock Exchange listing rule 10.4.1R (notification of class 2 transactions), the gross book value of assets subject to the divestment as of 31 December 2019 was nil. In 2019, 可定 generated Product Sales of $136m and Profit before Tax of $98m in the countries covered by the agreement. The consideration will be paid in cash and the proceeds used for general corporate purposes.
可定
可定 (rosuvastatin) is a statin, a lipid-lowering medicine, used to treat blood lipid disorders and to prevent cardiovascular events, such as heart attacks and strokes. 可定 produces its lipid modifying effects in two ways: it blocks an enzyme in the liver causing the liver to make less cholesterol, and it increases the uptake and breakdown by the liver of cholesterol already in the blood. 可定 is approved as a lipid regulating medicine in more than 100 countries.
澳门在线赌城娱乐
澳门在线赌城娱乐 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - 肿瘤学, 心血管, 肾 & Metabolism, and 呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门在线赌城娱乐.com and follow the Company on 推特 @澳门在线赌城娱乐.
联系人
For details on how to contact the 投资者关系 Team, please click 在这里. For 媒体联系人, click 在这里.
艾德里安·坎普
公司秘书
澳门在线赌城娱乐